The aim of this study was to determine whether standard treatments for Tobacco Dependence affect smoking-induced changes in intrasynaptic dopamine (DA) concentration. Forty-three otherwise healthy adult cigarette smokers (10 to 40 cigarettes per day) were treated with either practical group counseling (PGC) psychotherapy (n=14), bupropion HCl (n=14), or matching pill placebo (n=15) (random assignment) for 8 weeks. Before and after treatment, each subject underwent a bolus-plus-continuous-infusion (11)C-raclopride positron emission tomography (PET) scanning session, during which he or she smoked a regular cigarette. The PET scanning outcome measure of interest was percent change in smoking-induced (11)C-raclopride binding potential (BP(ND)) in the ventral caudate/nucleus accumbens (VCD/NAc), as an indirect measure of DA release. Although the entire study sample had a smaller mean smoking-induced reduction in VCD/NAc BP(ND) after treatment (compared to before treatment), this change was highly correlated with smaller total cigarette puff volumes (and not other treatment variables). These data indicate that smoking-induced DA release is dose-dependent, and is not significantly affected by reductions in daily smoking levels or treatment type.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2947623 | PMC |
| http://dx.doi.org/10.1016/j.pscychresns.2009.06.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of stimulant medication on loss of control eating in youth with attention deficit/hyperactivity disorder: a prospective, observational case series study protocol.
J Eat Disord
November 2022
Department of Psychiatry and Behavioral Sciences, University of Southern California, Los Angeles, CA, USA.
Background: Loss of control eating (LOC-E) in youth predicts the later development of full-syndrome binge-eating disorder (BED), and therefore, could be a relevant target for prevention treatments. To develop these treatments, it is important to understand the underlying disease processes and mechanisms. Based on the putative role of neurocognitive impairments in the pathogenesis of LOC-E, treatments that modulate these neurocognitive factors warrant further exploration.
View Article and Find Full Text PDFImaging synaptic dopamine availability in individuals at clinical high-risk for psychosis: a [C]-(+)-PHNO PET with methylphenidate challenge study.
Mol Psychiatry
June 2021
Department of Psychiatry and Behavioral Medicine, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY, USA.
Patients at clinical high-risk (CHR) for psychosis show elevations in [F]DOPA uptake, an estimate of dopamine (DA) synthesis capacity, in the striatum predictive of conversion to schizophrenia. Intrasynaptic DA levels can be inferred from imaging the change in radiotracer binding at D receptors due to a pharmacological challenge. Here, we used methylphenidate, a DA reuptake inhibitor, and [C]-(+)-PHNO, to measure synaptic DA availability in CHR both in striatal and extra-striatal brain regions.
View Article and Find Full Text PDFAltered levels of dopamine transporter in the frontal pole and dorsal striatum in schizophrenia.
NPJ Schizophr
December 2019
The Florey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia.
The dopamine hypothesis proposes that there is a hypodopaminergic state in the prefrontal cortex and a hyperdopaminergic state in the striatum of patients with schizophrenia. Evidence suggests the hyperdopaminergic state in the striatum is due to synaptic dopamine elevation, particularly in the dorsal striatum. However, the molecular mechanisms causing disrupted dopaminergic function in schizophrenia remains unclear.
View Article and Find Full Text PDFA cholecystokinin B receptor antagonist and cocaine interaction, phase I study.
CNS Neurosci Ther
January 2019
Medications Development Division, The National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, USA.
Aims: RPR 102681, a cholecystokinin-B antagonist, increased dopamine (DA) release and reduced cocaine self-administration in animals. This pilot study sought to assess the safety and pharmacokinetics (PK) of co-administration of RPR 102681 and cocaine, and to confirm the DA release mechanism of RPR 102681.
Methods: Sixteen cocaine-dependent participants were randomized to either placebo or RPR102681 at 3 ascending doses; cocaine was co-administered at steady state of RPR 102681.
Polymorphisms in dopaminergic system genes; association with criminal behavior and self-reported aggression in violent prison inmates from Pakistan.
PLoS One
September 2017
Department of Microbiology and Molecular Genetics, University of the Punjab, Lahore, Pakistan.
Genetic factors contribute to antisocial and criminal behavior. Dopamine transporter DAT-1 (SLC6A3) and DRD2 gene for the dopamine-2 receptor are dopaminergic system genes that regulate dopamine reuptake and signaling, and may be part of the pathogenesis of psychiatric disorders including antisocial behaviors and traits. No previous studies have analyzed DAT-1 and DRD2 polymorphisms in convicted murderers, particularly from Indian subcontinent.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!